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Use of Botulinum Toxin in Central Nervous System Disorders 
Julie Puvogel, Paige Torbet, Jourdan Ujlaki, Rebecca Worden, Lindsey Peters, PharmD, RPh, BCPS 
Abstract 
Botulinum toxin is a neurotoxin that is produced by Clostrid-
ium botulinum. At one time, this toxin was only seen as a le-
thal substance, but now scientists have found many medical 
uses for it. There are eight distinctive toxins (A-H), but only A 
and B currently have clinical uses. Botulinum toxin A has 
three different versions that are U.S. Food and Drug Admin-
istration (FDA) approved: onabotulinumtoxinA (Botox®), 
abobotulinumtoxinA (Dysport®), incobotulinumtoxinA (Xeo-
min®). Botulinum toxin 8 is also FDA approved as rimabotu-
linumtoxinB (Myobloc®). The toxins work by inducing 
reversible, local, dose-dependent chemodenervation by in-
hibiting acetylcholine release from presynaptic terminals. 
These drugs are approved to treat many different types of 
disorders but have found significant use for the treatment of 
migraines, dystonias and cerebral palsy. Botulinum toxin has 
proven to be efficacious in prophylactically treating those 
patients with migraines who have failed other pharmacologic 
and nonpharmacologic treatments. Botulinum toxin is also 
FDA approved for the treatment of dystonias; more specifi-
cally, all three types of botulinum toxin A and the rimabotuli-
numtoxin B have FDA approval for the treatment of cervical 
dystonia. Perhaps the most important use for botulinum tox-
in is in patients with cerebral palsy. Botulinum toxin is effica-
cious in patients with upper limb spasticity who are not good 
surgical candidates. It also proves useful as an adjunct to 
physiotherapy in these patients. This can help reduce or slow 
progression in patients with cerebral palsy. Exercise has 
been shown to be an efficacious treatment in patients with 
migraines, dystonias and cerebral palsy. Further research is 
necessary to determine the potential benefits the combina-
tion of exercise and botulinum toxin can have in these pa-
tients. While the high cost of botulinum toxin might deter 
some patients, it is a good option for those that have exhaust-
ed other options or are not good candidates for surgery. 
Key Terms 
Acetylcholine; Acetycholine Release Inhibitors; Botulinum 
Toxins Type A; Cerebral Palsy; Chronic Disease; Clostridium 
botulinum; Migraine Disorders; Muscle Spasticity; Nerve 
Block; Neurotoxins; Pharmaceutical Preparations; Physical 
Therapy Modalities; Presynaptic Terminals; Torticollis 
Introduction 
The application and knowledge of botulinum neurotoxin has 
increased exponentially since its first documentation in 1815 
by Professor Johann Heinrich Ferdinand Autenrieth.1 Justi-
nus Kerner made the first major breakthrough in the under-
standing of botulinum toxin several years later in 1822. 
Kerner found and recorded the symptoms of the toxin, hy-
potheses of pathophysiology and the idea that there were 
therapeutic uses for the toxin. Due to the human body's re-
sponse to botulinum toxin, Kerner proposed that small 
amounts should "reduce or block the hyperactivity and 
hyperexcitability of the motor and autonomic nervous 
system."1 Since this publication, several researchers have 
expanded upon this concept. The explorations of these re-
searchers have resulted in the first successful application of 
the gastric tube, the discovery of botulin um toxin-producing 
bacteria (Bacillus botulinus, later named Clostridium botuli-
num) and many additional therapeutic uses of botulinum 
toxin, some of which are examined below. In this article, bot-
ulinum toxin will be described including which preparations 
are currently available. The specific uses of botulinum toxin 
will be identified, .and clinical trials will be evaluated for bot-
ulin um toxin use in the diagnoses and treatment of mi-
graines, dystonias and cerebral palsy. The progression in the 
understanding of this toxin is evident as scientists have 
utilized a toxin that was once lethal to now treat numerous 
disorders and improve the quality of many lives. Further 
research will only continue to unveil new opportunities for 
the medical use of botulin um toxin. 
Botulinum Toxin 
Botulinum toxin is produced by Clostridium botulinum and 
includes eight antigenically distinct toxins, labeled A through 
H.2 Botulinum toxin is composed of a core neurotoxin and 
many nontoxic accessory proteins which protect and stabi-
lize it from temperature changes, variable pH and enzymatic 
degradation. The toxin is activated after secretion by scis-
sion, either with endogenous or exogenous proteases, and is 
then able to induce reversible, local, dose-dependent che-
modenervation by inhibiting acetylcholine release from pre-
synaptic nerve terminals. The binding domain of the toxin 
binds to presynaptic nerve endings and is internalized via 
endocytosis. The catalytic domain, a zinc endopeptidase, is 
released in the cytoplasm and irreversibly cleaves proteins 
that are essential for regulating exocytosis. This prevents the 
acetylcholine vesicles from fusing with the plasma mem-
brane, thus preventing the release of acetylcholine into the 
synaptic cleft. It takes approximately three months for new 
exocytosis regulating proteins to be resynthesized, which 
leads to a full recovery of the neuromuscular junction. 
After years of clinical use and repeated injections of botuli-
num toxin, sensitization has been known to occur.2 This 
sensitization is due to the formation of anti-botulinum toxin 
antibodies. These antibodies can be targeted against the core of 
botulinum toxin resulting in complete inhibition of the toxin. 
However, there can also be antibodies that are targeted against 
proteins in the toxin and therefore not interfere with the tox-
in's biological activity. The formation of these antibodies is the 
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main reason to be cautious when using botulinum toxin, as 
these antibodies can cause adverse effects for the patient. 
There are four main botulinum toxins used as pharmaceuti-
cals: onabotulinumtoxinA (Botox®), abobotulinumtoxinA 
(Dysport®), incobotulinumtoxinA (Xeomin®) and rimabotuli-
numtoxinB (Myobloc®).2 They differ in purity, potency, im-
munogenicity, complexity and manufacturing. 
There are many U.S. Food and Drug Administration (FDA) 
indications for the use of botulinum toxin (summarized in 
Table 1).3 Botulinum toxin is considered a first-line treat-
ment in patients with cervical dystonia (CD) which presents 
as a combination of dystonic movements and postures and, 
frequently, pain.2 The first choice of therapy for patients with 
blepharospasm, an involuntary closure of the eyelids, is also 
botulinum toxin; safety and efficacy have been proven in clin-
ical trials. There is also strong evidence in support of using 
botulinum toxin for upper limb spasticity. A common FDA 
approved indication is the treatment of glabellar lines, more 
commonly referred to as "frown lines."3 Other indications 
vary according to which toxin is being used. Onabotuli-
numtoxinA has the most indications, other than those al-
Table 1. A Summary of Available Botulinum Toxins.3 
ready mentioned, including axillary hyperhidrosis, chronic 
migraine, lateral canthal lines, lower limb spasticity, overac-
tive bladder, strabismus and blepharospasm associated with 
dystonia and urinary incontinence due to detrusor overactiv-
ity.3 
Adverse reactions to botulinum toxins can occur.3 The inci-
dence of the adverse reaction depends on what the toxin is 
being used to treat as well as the brand of the toxin. Some 
more prominent adverse reactions that have been reported 
to be caused from botulinum toxin include urinary tract in-
fection, urinary retention, headache, neck pain, injection site 
irritation, upper respiratory tract infection, dizziness and 
strabismus. Botulinum toxin is associated with an admin-
istration warning: botulinum toxin can spread beyond the 
site of injection and can cause life threatening injury such as 
dysphagia. 
Botulinum toxin is dosed in units, and it is recommended 
that the lowest dose should be used when initiating treat-
ment and increasing the dose as necessary to alleviate symp-
toms of disease.3 No dose adjustments are required for 
patients with renal or hepatic impairment. The onset of ac-
Generic Name AbobotulinumtoxinA lncobotulinumtoxinA OnabotulinumtoxinA RimabotulinumtoxinB 
(Brand Name) (Dysport®) (Xeomin®) (Botox®) (Myobloc®) 
Botulin um Type A Type A Type A TypeB Toxin Type 
Axillary hyperhidrosis 
(severe); blepharospasm 
associated with dystonia; 
cervical dystonia; migraine 
Blepharospasm, (chronic) prophylaxis; 
Cervical dystonia; 
cervical dystonia, overactive bladder; 
glabellar lines strabismus; upper limb Labeled glabellar lines (moderate to spasticity (severe); urinary Cervical dystonia lndication(s) (moderate to 
severe), incontinence (due to 
severe) 
upper limb spasticity detrusor overactivity 
associated with a neurologic 
condition) 
Cosmetic: Glabellar and 
lateral canthal lines 
(moderate to severe) 
Dosage Forms Injection, Injection, Injection, Injection, 
Available powder for solution powder for solution powder for solution solution 
Dosage 2,500 units per 0.5 SO, 100 and mL; Strengths 300 and 500 units 200 units 100 and 200 units 5,000 units per 1 mL; Available 10,000 units per 2 mL 
Route of IM IM IM, intradermal, IM Administration intradetrusor 
Adapted from: Lexicomp [Internet]. Hudson (OH) : Wolters Kluwer. 2016. 
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tion, represented by improvement of symptoms, can occur 
anywhere from days after injection to weeks after injection 
and is dependent on the toxin used. The toxin typically has a 
duration of months but is also dependent on toxin used and 
indication. 
It should be noted that botulinum toxin is costly. Depending 
on the brand, botulinum toxin can cost around $700 for 100 
units.3 Insurance coverage varies, though most insurances 
require a patient to be nonresponsive to at least one treat-
ment prior to trying botulinum toxin.4 In light of this, cost 
can be a major barrier to treatment for patients and should 
be weighed against other, less-costly treatment options. 
A review follows of the current nonpharmacologic and phar-
macologic treatment options for the three common indica-
tions: migraine, dystonia and cerebral palsy. An evaluation of 
the literature for both safety and efficacy is also included. A 
summary of the trials discussed is shown in Table 2. 
Migraines 
The prevalence of migraines varies by age and gender, but in 
the United States it is reported that more women than men 
experience migraine headaches.5 It has been reported that 
prevalence is highest in patients between 30 and 49 years of 
age. 
The etiology and pathophysiology of migraines are not com-
pletely understood, however, most clinicians believe the 
pathogenesis may be related to complex dysfunctions in 
neuronal and broad sensory processing.s The pain due to 
migraines is thought to come from activity within the trigem-
inovascular system, which is a network of visceral afferent 
fibers arising from the trigeminal ganglia and projects pe-
ripherally to innervate pain sensitive cranial blood vessels, 
dura mater and large venous sinuses. These fibers also pro-
ject centrally where they terminate in the trigeminal nucleus 
caudalis in the brainstem and upper cervical spinal cord 
providing a pathway for nociceptive transmission to the 
higher centers of the central nervous system (CNS). Activa-
tion of trigeminal sensory nerves releases vasoactive neuro-
peptides, which interact with dural blood vessels to promote 
vasodilation and dural plasma extravasation, causing neuro-
genic inflammation. Conduction along the trigeminovascular 
fibers transmits pain inputs to the trigeminal nucleus caudal-
is where the pain information is relayed to higher pain cen-
ters. Continued afferent input can cause sensitization of the 
central sensory neurons which produces a state that main-
tains the headache. It is thought that those who experience 
migraines have a lower threshold of response to specific en-
vironmental factors that govern the balance of CNS excitation 
and inhibition. The responsiveness of the migrainous brain 
may be due to genetic factors that cause abnormalities in ion 
channels and pumps that control the release of neurotrans-
mitters in the brain. 
Treatment strategies for migraines are generally individual-
ized, based on the patient's long-term and short-term goals, 
and usually aim to minimize headache-related disability and 
distress to improve the patient's quality of Iife.5 In general, 
treatment includes both pharmacologic and nonpharmaco-
logic options that are both prophylactic and symptomatic 
and depend on the severity of the migraine. It is noted when 
migraine medications are used frequently and/or excessive-
ly, a phenomenon occurs in which the headache symptoms 
recur with increased frequency or intensity. This is known as 
"rebound headaches" or "medication overuse" headaches. 
No specific treatments have been shown to be effective for 
this other than tapered withdrawal of the medications being 
overused. 
Nonpharmacologic treatment for migraines can include 
keeping a headache journal to identify triggers to avoid, per-
forming behavioral interventions such as relaxation therapy, 
and adhering to a general wellness program including sleep, 
exercise, healthy eating, smoking cessation and limiting caf-
feine intake.s The effects of aerobic exercise and yoga on mi-
graine severity and recurrence are based on limited research. 
According to a review of literature on these and other 
alternative treatment methods, studies have found opposing 
results, but recent research has shown positive effects on 
reduction of migraine symptomology.6 In a study of 72 
patients with migraines, headache intensity, medication use 
and pain ratings were found to be significantly lower 
(P <0.001) in the group who completed 12 weeks of 60 
minutes of yoga five times a week versus the control group.7 
Additionally, the intervention group displayed a significant 
decrease in anxiety and depression (P <0.001). A Turkish 
study examined the relationship between migraines and aer-
obic exercise delivered in three (one hour) sessions per week 
and reported that the severity, frequency and duration of 
migraines were decreased with regular activity compared to 
the control group.a Additional information regarding these 
and alternative treatment methods can be obtained from 
Karakurum Goksel's review of therapeutic options for mi-
graine patients.6 Due to the lack of research on these topics, 
the combination of botulinum toxin and exercise has not 
been examined. Further research should be conducted to 
determine whether the benefits of each treatment can be 
additive or synergistic for greater gains in symptom relief. 
Common pharmacologic treatments include analgesics and 
nonsteroidal anti-inflammatory drugs (NSAIDs).s Serotonin 
receptor agonists, such as sumatriptan, are also used as mi-
graine relief medications. Migraine relief is a result of nor-
malizing dilated intracranial arteries, inhibiting vasoactive 
neuropeptide release and inhibiting transmission to the thal-
amus. Beta adrenergic antagonists are most widely used for 
migraine prophylaxis. While the precise mechanism of how 
this class of drug prevents migraines is unknown, it is 
thought that they may raise the migraine threshold by 
modulating adrenergic or serotonergic neurotransmission in 
cortical or subcortical pathways. Antidepressants are also 
potentially beneficial in migraines most likely due to the 
downregulation of central serotonin receptors, increased 
levels of synaptic norepinephrine and enhanced endogenous 
opioid receptor actions. Anticonvulsants are emerging as an 
option in treating migraines, especially in patients who also 
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Table 2. Summary of Studies Discussed. 
Authors Study Design Disease State Main Endpoints Author's Conclusions Studied 
Randomized, Migraines Change in number of Botox® is an effective prophylactic 
DodickDW, double-blind, headache days treatment in migraine patients who 
MauskopA, placebo con- are not using any other prophylactic 
Elkind AH, trolled migraine medications. 
et al.4 
Jankovic J, Prospective, Cervical Clinical safety and OnabotulinumtoxinA is safe and 
Adler CH, observational, Dystonia efficacy of onabotuli- efficacious in the treatment of cervical 
Charles D, multicenter numtoxinA in cervical dystonia. 
et al.14 registry dystonia 
Evidente VGH, Randomized, Cervical Efficacy and safety of lncobotulinumtoxinA is safe and 
Fernandez HH, double-blind, Dystonia incobotulinumtoxinA for efficacious in the treatment of cervical 
LeDoux MS, repeated-dose cervical dystonia in dystonia. 
et al.15 repeated doses 
TruongD, Randomized, Cervical Long-term efficacy and Dysport® is safe and efficacious in 
BrodskyM, double-blind, Dystonia safety of Dysport® long-term treatment of cervical 
LewM, placebo dystonia. 
et al.16 controlled 
DresslerD, Prospective, Cervical Comparing potency of Similar therapeutic effect durations; 
Tacik P, open-label Dystonia the drugs Botox® and doses were exchanged ata 1:1 ratio, 
Saberi FA17 crossover study Xeomin® concluded similar efficacy and potency. 
YunJY, Randomized, Cervical Compared Dysport® and No significant difference between 
KimJW, double-blind, Dystonia Botox® by looking at groups in the TWSTRS ratings or the 
Kim HT, multicenter, changes in TWSTRS and Tsui scale; concluded that Dysport® 
et a1.1a non-inferiority, Tsui scale scores and Botox® are comparable at dosage 
two-period conversion of 2.5:1. 
crossover study 
Koman LA, Randomized, Cerebral palsy Assess efficacy of Those that received therapy had 
Smith BP, double-blind, (upper limb) botulinum toxin A on statistically significant improvement 
Williams R, placebo- Upper Extremity Rating in the Melbourne Assessment 
et al.24 controlled scale, HC, Modified compared to placebo, authors 
House Functional concluded that it was safe and a good 
Classification and option for patients who are not good 
Melbourne Assessment candidates for surgery. 
of Unilateral Upper Limb 
Function of patients 
Ferrari A, Randomized Spastic Study the effects of Botulin um therapy was significantly 
MaoretAR, placebo- hemiplegic botulinum toxin better than placebo when combined 
Muzzini S, controlled upper limb combined with with physiotherapy. 
et aJ.25 cerebral palsy physiotherapy measured 
by the Assisting Hand 
Assessment (AHA) 
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experience seizures, anxiety and bipolar illness. These agents 
are thought to be beneficial due to the modulation of the 
excitatory neurotransmitter glutamate and inhibition of sodi-
um and calcium ion channel activity. 
Botulinum toxin has been shown to inhibit the release of no-
ciceptive mediators, causing anti-nociceptive action separate 
from its neuromuscular activity.s Also, botulinum toxin has 
been shown to inhibit sensitization of central trigeminovas-
cular neurons, which is felt to be important in the develop-
ment, progression and maintenance of migraines. Thus, 
botulinum toxin has been an area of research for prophylaxis 
of migraine headaches. 
A randomized, double-blind, placebo-controlled study of 355 
patients experiencing 16 or more headache days during a 
30-day baseline period was conducted.4 The study included a 
30-day baseline period, followed by a 30-day, single-blind, 
placebo-run-in period in which placebo response was deter-
mined, followed by a nine month, double-blind treatment 
period in which patients received three treatment cycles of 
either Botox® or placebo, separated by 90 days. During the 
study, characteristics of the patient's headaches were record-
ed using an electronic telephone diary. The participants in 
the study were grouped into those taking prophylactic medi-
cations and those that were not. Of those that were not tak-
ing any prophylactic medication, 117 received the botulinum 
toxin and 111 received placebo. Analysis of these 228 pa-
tients was conducted. At baseline, the number of headache-
free days between these placebo and treatment groups were 
similar. The increase in headache-free days for the botulinum 
toxin group was 10 days, compared to the placebo group of 
6.7 days, and was statistically significant with a p-value of 
0.038. Mean usual headache severity decreased over the 
course of the study for both the placebo and the treatment 
group. However, the decrease was greater in the botulinum 
toxin group and was statistically significant from day 180 to 
day 270. This study also evaluated the use of acute headache 
pain medication in addition to either the toxin or the placebo. 
It was found that there was a statistically significant differ-
ence between the placebo and toxin group in the use of pain 
medication. The placebo group decreased by only 4.1 days, 
compared to the toxin group, which decreased its use of pain 
medication an average of 7.8 days. This study showed that 
headache symptoms improved in patients receiving botuli-
num toxin in all efficacy parameters studied. 
Jn another study, Mitchel and colleagues looked into the cost-
effectiveness and quality of life (QOL) improvements in using 
botulinum toxin to treat refractory migraine headaches.9 Sur-
veys were sent to 54 patients, and 32 were returned. The 
survey included six QOL measures: headache severity, head-
ache frequency, use of rescue medications, productivity/ 
absenteeism, recreational activities and life enjoyment. Par-
ticipants used a five-point scale to assess those categories, 
which were no improvement, little improvement, moderately 
improved, quite a bit improved, or extremely improved. A 
composite QOL score was calculated by summing up the 
measures for each category, and 73 percent of participants 
reported moderate or better improvement in overall 
migraine QOL measures. However, analysis of total migraine-
related pharmacy costs (cost of the toxin and overall mi-
graine-related medications) shows that costs went up by 
80.9 percent after initiating toxin treatment. There was no 
change in the number of migraine-related emergency room 
visits. Limitations with this study include a short 
follow-up period, the use of concomitant pain medications 
and no comparison group. 
For the treatment of chronic migraines, botulinum toxin ap-
pears to be as effective as current therapy, with a decreased 
need for additional pain medications. More large scale re-
search needs to be performed with standardization of injec-
tion site location and dosage to solidify efficacy and safety of 
the toxin and determine if there is a place for using the toxin 
to treat refractory migraines. 
Dystonias 
Dystonia is a type of prolonged muscle tone that presents in 
patients in many different ways and can be mistakenly diag-
nosed as Parkinson's disease due to the repetitive and shaky 
movements with which some people presenuo.11 Due to the 
underdiagnosis of dystonia, often due to misdiagnosing, the 
true prevalence is hard to calculate.10 The hallmark symp-
toms of dystonias are dystonic postures and movements 
(flexing or twisting movements, rigidity), sensory tricks (a 
trick is touching the affected body part to relieve dystonia), 
mirror dystonias (repetitive movements occur in a nonaffect-
ed limb) and overflow dystonias (dystonia occurring in an 
atypical body region for the patient).11 The etiology is broken 
down into multiple parts, so it is important to classify the 
cause and type of dystonia in order to improve quality of life 
for the patient. The 2011 guidelines for dystonia provide a 
classification system to differentiate the types instructing 
clinicians to look at the etiology of the dystonia, the age of 
onset (early or late) and the distribution (focal, segmental, 
multifocal, generalized or hemidystonia).10 Genetic testing 
can be done on symptomatic individuals to diagnose certain 
types of dystonia as well. For the most part, each type of dys-
tonia has its own validated rating scale to evaluate the dis-
ease, monitor progression and predict impact on quality of 
life. 
In general, nonpharmacologic treatment options that are 
utilized include occupational therapy, physical therapy, deep 
brain stimulation and selective peripheral denervation and 
myectomy.12 Common medication classes that doctors pre-
scribe for dystonias are skeletal muscle relaxants (especially 
intrathecal baclofen), anticholinergic drugs, anticonvulsant 
drugs, anti-dopaminergic drugs and dopaminergic drugs. The 
guidelines do suggest the use of botulinum toxin for different 
types of dystonias. As mentioned above, all three formula-
tions of botulinum toxin A and botulinum toxin B are FDA 
approved for the treatment of cervical dystonia (CD).10.13 
OnabotulinumtoxinA (Botox®) had previously been the gold 
standard in cervical dystonia treatment. It was the first botu-
linum toxin that the FDA approved and has demonstrated 
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safety and efficacy in a prospective, observational registry 
that tracked 502 patients receiving Botox® for cervical 
dystonia.14 lncobotulinumtoxinA (Xeomin®) is a newer 
preparation of botulinum toxin that does not have accessory 
proteins, which helps prevent possible immunogenicity 
problems. It, too, has shown to be efficacious and safe in a 
double-blind, repeated-dose 88 week study.is Similarly, the 
third type ofbotulinum toxin, abobotulinumtoxinA (Dysport®) 
demonstrated efficacy in a randomized, double-blind, placebo-
controlled study, followed by an open-label extension.16 
Botulinum toxin B was noninferior to Botox® for the treatment 
of cervical dystonia in a randomized, double-blind, noninferi-
ority trial.13 Therefore, in today's practice, botulinum toxin B 
can be used as an alternative to botulinum toxin A.10 
Because all three types ofbotulinum toxin A are safe and effi-
cacious, studies are now comparing the different types. In a 
prospective, open-label crossover study comparing Botox® 
and Xeomin®, researchers compared the time between the 
injection and when the patient reported a decrease in the 
therapeutic effect.17 They also compared the potency of the 
two drugs by giving participants at least four injection series 
of each drug at a 1:1 dose ratio. The mean time to decrease in 
therapeutic effect was 11.2 ± 1.1 weeks for Botox®, com-
pared to Xeomin®, which had a time to decrease in effect of 
11.4 ± 1.3 weeks. Researchers concluded that because there 
were similar therapeutic effect durations and that the doses 
were exchanged at a 1:1 ratio, Botox® and Xeomin® have 
similar efficacy and potency. 
Similarly, researchers compared Dysport® and Botox® in a 
randomized, double-blind, multicenter, noninferiority, two-
period crossover study.1s The purpose of this study was to 
determine if a 2.5:1 ratio was an adequate conversion by 
looking at changes in the Tsui scale and the Toronto Western 
Spasmodic Torticollis Rating Scale (TWSTRS) from baseline 
to follow-up (weeks 4, 8, 12, and 16). The Tsui scale is a short 
rating system that looks at sustained movement amplitudes, 
duration, shoulder elevation and dystonic tremor but does 
not assess how cervical dystonia affects a patient's daily 
life.19 The TWSTRS is a validated scale that does look at the 
impact on a patient's life by summing up three different cate-
gories related to the participants' experience with cervical 
dystonia: severity, disability and pain.16 They also evaluated 
the participants' preferences and the reasons for their pref-
erences.rn There was no significant difference between 
groups in the TWSTRS ratings, and while participants' rat-
ings in the Tsui scale favored Botox®, the difference was not 
significant. When asked, more participants chose Dysport® 
(n=36) to Botox® (n=34), and 21 participants said they did 
not have a preference. In both cases of preference, the main 
reason that was given by patients was a perceived increase 
in efficacy. Adverse events were not statistically different 
between the two groups. Because neither version had a sta-
tistically significant preference, both drugs are comparable at 
a dosage conversion of 2.5:1 Dysport® to Botox®. 
Since the three forms are all efficacious, safe and comparable, 
it is important to consider the cost-effectiveness to deter-
mine the best option for a patient. In a cost-utility analysis, 
authors compared Botox®, Dysport® and Xeomin® use in cer-
vical dystonia from a federal government payer perspective. 
Outcomes were evaluated by measuring quality-adjusted life 
years (QALYs).20 Assuming a willingness-to-pay value of 
$100,000 per QALY, all three formulations are considered 
cost-effective; however, the most effective was Xeomin® 
with a cost-effectiveness ratio of $27,548 per QALY, followed 
by Dysport® ($36,678), and Botox® ($49,337). The QALY 
gained in a one-year period was comparable with 0.06 QAL Y 
gained for Dysport® and 0.07 QAL Y gained for both Xeomin® 
and Botox®. The authors of the analysis also looked at wastage 
during injections because each manufacturer recommends 
using one vial per patient. Dysport® had the lowest wastage 
(2.2 percent) followed by Xeomin® (10 percent) and Botox® 
(22.9 percent). Xeomin® has an advantage over Botox®; it is 
available in SO unit vials, whereas the smallest vial available 
for Botox® contains 100 units. The 50 unit vial allows for dose 
individualization with less waste. This analysis provides a use-
ful comparison between the drugs from a cost perspective. 
A current area of dystonia research surrounds the 
combination of exercise and botulinum toxin injections. In-
duced muscle weakness can result from botulinum toxin due 
to neuroparalysis and denervation.21 Inclusion of treadmill 
training programs has been assessed in rats to examine the 
results of this combination. Researchers found that exercise 
diminished muscle atrophy following injections and positive-
ly affected muscle contractile strength recovery. There is a 
possibility that treadmill training could cancel out the 
response of spasticity reduction from the botulinum toxin 
injection. The current knowledge base does not include re-
search that has confirmed or denied these theories in human 
participants. Due to the nature of both methods, this relation-
ship should be explored to determine the effect on patients 
with muscle spasticity, including patients with dystonias. 
Cerebral Palsy 
Cerebral palsy is a debilitating disease that starts in infancy 
or young children.22 Currently, it is the number one cause of 
childhood disabilities. The disease begins when damage oc-
curs to the cerebral cortex either during fetal development, 
during birth, or after birth and is permanent. Types of dam-
age could be periventricular leukomalacia, cerebral dysgen-
esis, intracranial hemorrhage or a lack of oxygen. It manifests 
in a variety of symptoms such as limb weakness, spasticity, 
crouched gait, ataxia and delays in reaching motor skill mile-
stones. Every patient with cerebral palsy will have individu-
alized presentation and severity of the disease. Doctors can 
diagnose the disease by testing motor skills, monitoring mo-
tor development and performing neuroimaging techniques 
like cranial ultrasounds, computed tomography (CT) and 
magnetic resonance imaging (MRI). While this disease is not 
curable, botulinum toxin has become a standard of treatment 
for cerebral palsy patients of all ages to help improve gait 
function by controlling spasms. 
Nonpharmacologic options might include surgeries like rhi-
zotomy to kill certain nerve roots responsible for cerebral 
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palsy or peripheral neurectomy to remove the nerves.23 Or-
thopedic surgical options might include tendon lengthening 
or transfer, osteotomy or joint fusion to help with movement. 
Oral treatment options for cerebral palsy include dantrolene 
sodium, baclofen, tizanidine and benzodiazepines. Patients 
can also receive parenteral therapy to aid in chemical dener-
vation, such as ethanol 45 to 100 percent, phenol S to 7 per-
cent, botulinum toxin or intrathecal baclofen. Because not all 
patients are good surgical candidates, and botulinum toxin is 
not something a patient has to receive every day, it becomes 
a good option for many patients. 
Children with cerebral palsy that affects their upper extremi-
ties often have spasticity patterns like internal shoulder rota-
tion, elbow flexion, forearm pronation, wrist and finger flex-
ion and thumb-in palm.24 Many of these patients are not good 
candidates for surgery due to their age, so botulinum toxin 
therapy would be a good option to help control spasms until 
they are a better candidate for surgery. In a randomized, 
double-blind, placebo-controlled study of botulinum toxin A, 
researchers used the House Classification (HC) system to 
rate participants' functional ability. The participants received 
either botulinum toxin A or placebo at baseline, week 8, and 
week 20 if indicated. Visits were conducted at baseline and 
weeks 4, 8, 14, 20 and 26. At the visits where the patient re-
ceived an injection, the patient met independently with both 
a physician and an occupational therapist, and if the visit did 
not include an injection, the patient was evaluated by just the 
occupational therapist. Doses were individualized to the pa-
tient, and if the physician felt that the patient did not need 
another injection the injection was not given at that appoint-
ment. The physician evaluated based on the Upper Extremity 
Rating scale (used to evaluate the range of motion of the 
limbs), the HC, and the Modified House Functional Classifica-
tion. The occupational therapist used these same scales along 
with the Melbourne Assessment of Unilateral Upper Limb 
Function. The study also looked at Health-Related Quality of 
Life outcomes for the caregivers and also safety of botulin um 
toxin A by assessing any adverse events. 
The study showed that the patients in the botulinum toxin A 
group had a statistically significant improvement in the Mel-
bourne Assessment compared to placebo.24 The study also 
showed a better improvement in the mean range of motion 
at weeks 20 and 26 for the botulinum toxin A group. There 
was not, however, any difference in the Health-Related Quali-
ty of Life data for the caregivers. Botulinum toxin A did prove 
to be relatively safe for the patients in the study with only 
mild to moderate adverse events reported such as muscle 
soreness at the injection site, muscle cramps, excessive 
weakness, headache, rash and fatigue. Overall, the study 
proved that botulinum toxin A is a good option for those pa-
tients with upper limb spasticity related to cerebral palsy 
that are not currently candidates for surgery. 
In a similar randomized, placebo-controlled trial, botulinum 
toxin was compared with placebo in children with spastic 
hemiplegic upper limb cerebral palsy.zs One of the major dif-
ferences in the study was that the injections were combined 
with physiotherapy. The participants received injections at 
baseline and had follow-up visits at one, three and six 
months. The participants also had a physiotherapy program 
that included three (45 minute) weekly sessions for 24 
weeks. The program included activities started out as uni-
manual and then moved bimanual and more complex as the 
study progressed. After the injection, participants received a 
customized positional splint. The study used the Assisting 
Hand Assessment (AHA) scale as a primary outcome to 
measure the use of the affected upper limb. Both the placebo 
group and the botulinum toxin A group showed improve-
ment in the AHA score after receiving an injection and physi-
otherapy, but the botulinum toxin A group showed a faster 
and more substantial change. At the six month visit, the botu-
linum toxin group stopped showing improvement, while the 
placebo group continued to change. This correlates with oth-
er studies that concluded that the average length of effective-
ness for botulinum toxin injections is around 12 weeks.17 
Because this study was small (only 27 participants), further 
studies need to be done on larger groups over a longer peri-
od of time; however, this study did confirm that botulinum 
toxin is effective in these patients, and that physiotherapy 
works as an adjunct when individualized to each patient.Zs 
The treatment of cerebral palsy can vary due to the patient's 
needs. One common component of cerebral palsy treatment 
is exercise. It has been found that the inclusion of treadmill 
exercises benefits the symmetry, speed and endurance of 
cerebral palsy patients.26 Spasticity of muscles results in 
weak lower extremity muscles and bone development due to 
the delay in independent ambulation. In a study of 37 chil-
dren with diagnosed cerebral palsy, an experimental group 
completed treadmill sessions twice a week for three months 
in addition to rehabilitation programs twice a week. At the 
conclusion of the study, the results between the treadmill 
program participants and the control group, who did not ex-
ercise, were compared. Participants who completed tread-
mill exercise were able to walk significantly faster, longer 
and farther during the postparticipation testing (p<0.001). 
The results of this study supported the conclusion that had 
been found and documented previously; ambulation and ex-
ercise tolerance are improved with the inclusion of treadmill 
exercise. Various exercise methods were examined for effects 
on postural control of cerebral palsy patients in a meta-
analysis performed by Dewar, Love and Johnston.27 
Treadmill training was supported as well as gross motor task 
training, hippotherapy, trunk-targeted training and reactive 
balance training. 
In theory, the combination of exercise and botulinum toxin 
should compound the benefits of these treatments and re-
duce the potential adverse effect of nontargeted muscle 
weakness. In a study of 15 children, 10 weeks of a home 
strength program were performed three times a week in pa-
tients who also received Botulinum Type-A (BoNT-A) injec-
tions.zs Significant results were documented in both groups 
that participated in the exercise program; one before the in-
jections and the other after. The levels of muscle spasticity 
were reduced, in addition to increased strength in the exer-
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cise and BoNT-A combined treatment group. As recorded in 
this study, the inclusion of exercise in conjunction with botu-
linum toxin injections can have a profound impact in cerebral 
palsy patients. Further research should continue to examine 
the timing, exercise method and other types of botulinum 
toxin for optimal treatment development. 
Conclusion 
Botulinum toxin has been established as an integral part in 
the treatment of disorders caused by muscle overactivity. 
Many clinical trials, shown in Table 2, have confirmed the 
safety and efficacy of its use. The benefits of the botulinum 
neurotoxin in the treatment of migraines, dystonias and cere-
bral palsy are only some of the uses for the toxin in the 
health care field. Botulinum toxin has also been included in 
the treatment of many ophthalmological disorders and 
movement disorders and continues to undergo testing for 
applications in smooth muscle overactivity disorders and 
hypersecretion of glands.29 Although some adverse effects 
can occur, the discovery and use of this toxin has led to a 
higher quality of life for many patients with various disor-
ders. The use of this drug in combination with other forms of 
treatment has the potential for even greater outcomes for 
patients. Further research will increase the impact botuli-
num toxin will have on the progression of treatments for dis-
orders of spasticity. 
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